NASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $292.84 +0.04 (+0.01%) As of 12:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Amgen Stock (NASDAQ:AMGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amgen alerts:Sign Up Key Stats Today's Range$291.90▼$295.9750-Day Range$258.59▼$307.8152-Week Range$253.30▼$346.85Volume529,245 shsAverage Volume3.07 million shsMarket Capitalization$157.41 billionP/E Ratio38.80Dividend Yield3.25%Price Target$314.09Consensus RatingHold Company OverviewAmgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.Written by Jeffrey Neal JohnsonRead More… Amgen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreAMGN MarketRank™: Amgen scored higher than 90% of companies evaluated by MarketBeat, and ranked 109th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 11 buy ratings, 10 hold ratings, and 2 sell ratings.Amount of Analyst CoverageAmgen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth3.59% Earnings GrowthEarnings for Amgen are expected to grow by 3.59% in the coming year, from $20.60 to $21.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 38.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 38.78, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.97.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.53. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 26.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.38% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amgen has recently increased by 11.46%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 3.27%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Amgen is 126.09%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 44.61% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. Sustainability and ESG3.9 / 5Environmental Score-2.42 Percentage of Shares Shorted2.38% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amgen has recently increased by 11.46%, indicating that investor sentiment is decreasing significantly. News and Social Media4.1 / 5News Sentiment1.41 News SentimentAmgen has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 58 news articles for Amgen this week, compared to 27 articles on an average week.Search Interest91 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 146% compared to the previous 30 days.MarketBeat Follows33 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 32% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,410,596.00 in company stock.Percentage Held by InsidersOnly 0.69% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Email Address AMGN Stock News HeadlinesInsider Selling: Amgen Inc. (NASDAQ:AMGN) EVP Sells $2,585,603.09 in StockFebruary 14, 2025 | insidertrades.comAmgen Inc. (NASDAQ:AMGN) EVP Jonathan P. Graham Sells 25,045 SharesFebruary 11, 2025 | insidertrades.comDividendStocks for BeginnersIf you’re not familiar with how to build a strong, reliable dividend portfolio… or where to begin… We’ve got the hookup for you. A young investor who’s obsessed with dividends put together a set of 5 dividend “cheat sheets” meant to take you from 0 to what could be a full blown dividend portfolio as quickly as possible… The best part? Right now, the five dividend cheat sheets are FREEFebruary 19, 2025 | ProsperityPub (Ad)Nancy A. Grygiel Sells 1,589 Shares of Amgen Inc. (NASDAQ:AMGN) StockFebruary 7, 2025 | insidertrades.comEarnings Miss? Amgen’s Dividend Still a Bright SpotFebruary 5, 2025 | dividendstocks.comShort Interest in Amgen Inc. (NASDAQ:AMGN) Rises By 11.5%February 17 at 3:45 AM | americanbankingnews.com6AMGN : Amgen Unusual Options Activity For February 12February 14, 2025 | benzinga.comAmgen Inc (AMGN) to Present at Citi's 2025 Virtual Oncology Leadership SummitFebruary 14, 2025 | gurufocus.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $260.64 at the beginning of the year. Since then, AMGN shares have increased by 12.3% and is now trading at $292.6650. View the best growth stocks for 2025 here. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, February, 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a trailing twelve-month return on equity of 176.32% and a net margin of 12.24%. Read the conference call transcript. Does Amgen have any subsidiaries? Amgen subsidiaries include TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more. Who are Amgen's major shareholders? Top institutional investors of Amgen include Vanguard Group Inc. (9.81%), Charles Schwab Investment Management Inc. (2.46%), Primecap Management Co. CA (2.42%) and Geode Capital Management LLC (2.32%). Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Meta Platforms (META), Chevron (CVX), Verizon Communications (VZ), Bristol-Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD). Company Calendar Ex-Dividend for 12/9 Dividend11/18/2024Dividend Payable12/09/2024Last Earnings2/04/2025Ex-Dividend for 3/7 Dividend2/14/2025Today2/19/2025Dividend Payable3/07/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CUSIP03116210 CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees26,700Year Founded1980Price Target and Rating Average Stock Price Target$314.09 High Stock Price Target$405.00 Low Stock Price Target$195.00 Potential Upside/Downside+7.3%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)$7.55 Trailing P/E Ratio38.78 Forward P/E Ratio14.22 P/E Growth3.01Net Income$6.72 billion Net Margins12.24% Pretax Margin13.79% Return on Equity176.32% Return on Assets11.71% Debt Debt-to-Equity Ratio9.62 Current Ratio1.26 Quick Ratio0.96 Sales & Book Value Annual Sales$33.42 billion Price / Sales4.71 Cash Flow$21.02 per share Price / Cash Flow13.93 Book Value$10.93 per share Price / Book26.79Miscellaneous Outstanding Shares537,530,000Free Float533,824,000Market Cap$157.39 billion OptionableOptionable Beta0.56 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:AMGN) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.